Another active clinical trial involves the studies on the safety and tolerability of idasanutlin in combination with atezolizumab (Tecentriq, anti-PD-L1 antibody, a drug approved as a single therapy for various cancers [203]) and MEK inhibitor, cobimetinib. This evidence concerns the gene MAP2K7 and cancer.